[go: up one dir, main page]

MX2018008421A - Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. - Google Patents

Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.

Info

Publication number
MX2018008421A
MX2018008421A MX2018008421A MX2018008421A MX2018008421A MX 2018008421 A MX2018008421 A MX 2018008421A MX 2018008421 A MX2018008421 A MX 2018008421A MX 2018008421 A MX2018008421 A MX 2018008421A MX 2018008421 A MX2018008421 A MX 2018008421A
Authority
MX
Mexico
Prior art keywords
subject
predicator
biomarkers
therapies
methods
Prior art date
Application number
MX2018008421A
Other languages
English (en)
Other versions
MX390772B (es
Inventor
Filvaroff Ellen
Lopez-Girona Antonia
Lu Gang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018008421A publication Critical patent/MX2018008421A/es
Publication of MX390772B publication Critical patent/MX390772B/es

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57505—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método para identificar un sujeto que tiene cáncer que es probable que responda a un compuesto de tratamiento, que comprende administrar el compuesto de tratamiento al sujeto que tiene cáncer; obtener una muestra del sujeto; determinar el nivel de un biomarcador en la muestra del sujeto; y diagnosticar al sujeto como que es probable que responda al compuesto de tratamiento si el nivel del biomarcador en la muestra del sujeto cambia en comparación a un nivel de referencia del biomarcador; donde el compuesto de tratamiento es un compuesto de Fórmula I: (Véase formula).
MX2018008421A 2016-01-08 2017-01-06 Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. MX390772B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276700P 2016-01-08 2016-01-08
US201662404638P 2016-10-05 2016-10-05
PCT/US2017/012496 WO2017120446A1 (en) 2016-01-08 2017-01-06 Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Publications (2)

Publication Number Publication Date
MX2018008421A true MX2018008421A (es) 2019-12-09
MX390772B MX390772B (es) 2025-03-21

Family

ID=59274055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008421A MX390772B (es) 2016-01-08 2017-01-06 Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.

Country Status (10)

Country Link
US (3) US10648983B2 (es)
EP (1) EP3399980B1 (es)
JP (3) JP6880037B2 (es)
KR (1) KR20180095094A (es)
AU (1) AU2017205170B2 (es)
CA (1) CA3010801A1 (es)
ES (1) ES3042541T3 (es)
IL (2) IL296659A (es)
MX (1) MX390772B (es)
WO (1) WO2017120446A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077548B1 (en) 2013-12-06 2021-11-10 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
MX2018003697A (es) 2015-09-25 2018-08-01 Celgene Corp Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
US11525165B2 (en) 2017-12-20 2022-12-13 Inserm Method of selection of an IRE1-inhibitor therapy for patient suffering from cancer
EP3774815A1 (en) * 2018-03-30 2021-02-17 Biotheryx Inc. Thienopyrimidinone compounds
JP7495886B2 (ja) * 2018-05-23 2024-06-05 セルジーン コーポレイション 多発性骨髄腫を治療すること及び４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルのバイオマーカーの使用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN114761400B (zh) * 2019-09-12 2024-08-13 南京明德新药研发有限公司 一种可降解蛋白的并环类化合物及其应用
BR112022007932A2 (pt) * 2019-10-28 2022-07-12 Celgene Corp Métodos para tratamento de leucemia e uso de uma assinatura de células-tronco leucêmicas para predizer sensibilidade clínica a terapias
EP4051275A4 (en) * 2019-10-28 2024-02-07 Celgene Corporation USE OF BIOMARKERS TO PREDICT CLINICAL SENSITIVITY TO 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXO-ISOINDOLIN-5-YL)METHYL)-2, 2-DIFLUOROACETAMIDE
US11031119B2 (en) * 2019-11-13 2021-06-08 Cube Click, Inc. Dental images processed with deep learning for national security
KR20220110795A (ko) * 2019-12-06 2022-08-09 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 제조 방법
KR102311390B1 (ko) * 2020-03-03 2021-10-13 이화여자대학교 산학협력단 교모세포종 예후예측용 조성물
AU2021239822A1 (en) * 2020-03-16 2022-10-13 Celgene Corporation Combination therapy for acute myeloid leukemia
WO2021211742A1 (en) * 2020-04-14 2021-10-21 The General Hospital Corporation Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction
EP4171557A1 (en) 2020-06-25 2023-05-03 Tolremo Therapeutics AG Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
AU2021347238A1 (en) 2020-09-23 2023-06-01 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
WO2022152822A1 (en) * 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Treatment of myc-driven cancers with gspt1 degraders
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
GB202104635D0 (en) * 2021-03-31 2021-05-12 Imperial College Innovations Ltd Methods and compositions for identifying and treating GCN2-dependent cancers
JP2024515061A (ja) * 2021-04-07 2024-04-04 トルレモ・セラピューティクス・アクチェンゲゼルシャフト 複素環誘導体、医薬組成物およびがんの治療または軽快におけるこれらの使用
EP4323349A1 (en) * 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
KR102823538B1 (ko) 2021-11-09 2025-06-23 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
WO2023085785A1 (ko) 2021-11-09 2023-05-19 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
CN114660289A (zh) * 2022-03-03 2022-06-24 中山大学附属第三医院 肝癌标志物及其应用
WO2023201282A1 (en) * 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
US20240115557A1 (en) * 2022-07-29 2024-04-11 The Brigham And Women's Hospital, Inc. Inhibitors of rna-guided nucleases and uses thereof
US20240150368A1 (en) * 2022-09-02 2024-05-09 Deciphera Pharmaceuticals, Llc Ulk inhibitors and methods of use thereof
JP2025531194A (ja) * 2022-09-16 2025-09-19 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 心臓アミロイドーシスの処置のためのｂａｇ３の方法および使用
KR20240066904A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR20240066906A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR102570883B1 (ko) * 2023-04-13 2023-08-29 (주) 사이러스테라퓨틱스 신규한 gspt1 분해제 및 이의 용도
WO2025164957A1 (ko) * 2024-01-31 2025-08-07 남부대학교산학협력단 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1574740A (en) * 1924-04-07 1926-02-23 Raynor John Roscoe Cutting device
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2131543C (en) 1992-03-04 2002-09-17 Daniel Pinkel Comparative genomic hybridization
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0103527D0 (en) 2001-02-13 2001-03-28 Eastman Kodak Co Photographic developing composition and use thereof in the development of a photographic element
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
JP2008545399A (ja) * 2005-05-18 2008-12-18 ワイス 白血病疾患遺伝子およびその使用
SG195613A1 (en) 2008-10-29 2013-12-30 Celgene Corp Isoindoline compounds for use in the treatment of cancer
AU2011224166B2 (en) 2010-03-12 2014-08-21 Celgene Corporation Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3904875B1 (en) 2012-06-29 2024-11-20 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
TW201534305A (zh) * 2013-05-03 2015-09-16 Celgene Corp 使用組合療法治療癌症之方法
EP3077548B1 (en) 2013-12-06 2021-11-10 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US20160312292A1 (en) 2013-12-06 2016-10-27 Celgene Corporation Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US20170242014A1 (en) 2014-10-13 2017-08-24 Celgene Corporaton Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
WO2017024019A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US20180231561A1 (en) 2015-08-12 2018-08-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
MX2018003697A (es) 2015-09-25 2018-08-01 Celgene Corp Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.
EP3399981B1 (en) * 2016-01-08 2023-08-02 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
BR112018013884A2 (pt) * 2016-01-08 2018-12-18 Celgene Corp formulações de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
JP7163281B2 (ja) * 2016-06-06 2022-10-31 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドによる血液系悪性腫瘍の治療

Also Published As

Publication number Publication date
US10648983B2 (en) 2020-05-12
US20230064156A1 (en) 2023-03-02
EP3399980A4 (en) 2019-09-04
US11460471B2 (en) 2022-10-04
JP2022166014A (ja) 2022-11-01
US20200333340A1 (en) 2020-10-22
WO2017120446A1 (en) 2017-07-13
KR20180095094A (ko) 2018-08-24
JP6880037B2 (ja) 2021-06-02
MX390772B (es) 2025-03-21
IL260400B (en) 2022-10-01
IL260400A (es) 2018-08-30
JP2019504063A (ja) 2019-02-14
IL296659A (en) 2022-11-01
US20170199193A1 (en) 2017-07-13
EP3399980A1 (en) 2018-11-14
JP2021121799A (ja) 2021-08-26
ES3042541T3 (en) 2025-11-21
AU2017205170A1 (en) 2018-07-19
IL260400B2 (en) 2023-02-01
JP7113942B2 (ja) 2022-08-05
EP3399980B1 (en) 2025-07-16
AU2017205170B2 (en) 2021-06-24
US12474342B2 (en) 2025-11-18
CA3010801A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2020004567A (es) Metodos diagnosticos y terapeuticos para el cancer.
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
MX2023010805A (es) Metodos terapeuticos y de diagnostico para el cancer.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
SV2017005577A (es) Metodos para diagnosticar y tratar el cancer
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
EP4306934A3 (en) Bodily emission analysis
MX2016002165A (es) Beneficio de supervivencia en pacientes con tumores solidos con niveles elevados de proteina c reactiva.
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
MX2021014963A (es) Metodos para predecir el beneficio terapeutico de la terapia con anti-cd19 en pacientes.
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.